Chemistry, manufacturing and controls: the product evidence
In one sentence
Chemistry, manufacturing and controls describes a drug or biological product, how it is made and the evidence used to control its quality.
The intuition
Think of a product dossier as a map with supporting evidence. It tells a reviewer what the product is, how it is made and how its important features are checked. A map labeled “complete” is less useful than one whose claims can be traced to actual measurements.
The analogy stops at the paperwork. Chemistry, manufacturing and controls (CMC) depends on studies and operating experience, not polished descriptions alone. For living-cell products, “chemistry” does not restrict the dossier to chemical measurements.
How it works
Start by defining the product. A sequence, cell population or formulation needs a specified version and composition. The manufactured active material and the final administered formulation may have different descriptions and controls. A product name alone leaves these relationships unclear.
Next describe the manufacturing process and its materials. Identify steps or attributes whose variation could affect quality. A critical quality attribute is an important product characteristic to keep within justified limits. A processing setting and the resulting product attribute are related, but are not the same measurement.
The evidence then connects methods to claims. A specification identifies tests, their procedures and acceptance criteria. A criterion is meaningful only with a suitable method and an explanation of what the result represents. Potency and identity answer different questions.
Stability asks whether relevant quality persists under specified storage, transport and use conditions. A result at manufacture does not establish every later condition. Changes require assessment of whether earlier evidence still applies. These elements are described in the United States Food and Drug Administration (FDA) gene-therapy CMC guidance.
The dossier connects product, process and evidence. Review in context is not an automatic authorization or a clinical-benefit claim.
Why it matters in cancer
A personalized construct may change while using a shared manufacturing platform. Reusing a process can be useful, but the relationship between the new product and earlier evidence still needs support. Likewise, changing a cell-processing step can affect features beyond the final cell count.
Evidence develops with the program. FDA's May 2026 guidance describes product- and stage-dependent CMC flexibility for cell and gene therapies moving toward a biologics license application. Flexibility is not a universal exemption from quality requirements. An investigational submission and a marketing application are different review settings.
How it is assessed
| Dossier question | Example evidence | Tempting overread |
|---|---|---|
| What is the product? | Composition and identity | A name fixes every attribute |
| How is it made? | Process description and controls | A diagram proves reproducibility |
| What does it do in a test? | Relevant activity assay | Laboratory activity proves benefit |
| What happens over time? | Stability under stated conditions | One time point covers every journey |
These are learning questions, not an application template.
Worked example and practice
A fictional vaccine dossier describes version A and its storage studies. Version B changes the formulation. The old studies show something about A; the shared sequence does not establish B's delivery or stability.
Try it: Can the old dossier simply be relabeled B?
One possible answer
No. The changed formulation needs to be identified and its effect assessed. A comparability assessment may connect relevant evidence, but the example supplies no such conclusion.
Common confusions
- CMC is the product-quality evidence, not a synonym for a facility's GMP framework.
- A certificate of analysis summarizes a lot's named tests; it is not the entire dossier.
- Product characterization can be broader than routine release testing.
- Quality, regulatory authorization and clinical efficacy remain separate questions.
Explain it back
“CMC connects ___; its requirements depend on ___.” One answer: “the product, process and quality evidence; the product and development stage.”
Takeaway
Read the product, process and quality evidence together.
Related concepts
Sources and scope
Source check: October 10, 2026. General dossier concepts, illustrated by United States cell/gene-therapy guidance. Actual expert and learner review remains pending.
- FDA: gene-therapy CMC information for investigational applications, January 2020, product description, specifications and stability sections.
- FDA: CMC flexibilities for cell/gene-therapy biologics license applications, May 2026.